A study reporting on DiscGenics’ cell therapy phase 1 and 2 study has been selected as one of three of the best and most influential articles published in the International Journal of Spine Surgery in ...

Degenerative disc disease is common among young adults with PsA, with key risk factors including older age, male sex, diabetes, and inflammatory back pain.

DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company developing allogeneic, cell-based, regenerative therapies for musculoskeletal degeneration, today announced that the ...